The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi (SNY).

French pharmaceutical giant Sanofi said Tuesday it will pay $1.15 billion to acquire the privately held London-based private ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Vicebio is currently running an exploratory Phase 1 clinical trial with lead asset VXB-241, a bivalent vaccine targeting both RSV and hMPV viruses, pathogens that are a significant burden in the ...

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...